But that formula didn't seem to pass the mustard with the buyout of five prime?
peak sales for all indications would've been 305m, but bought out for 1.9b. No discount for trial stage(finished P2)
obviously just anecdotal and not taking into account all statistical data. But are more recent buyout becoming more feverish by big pharma?
But that formula didn't seem to pass the mustard with the buyout...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 31396 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |